Cargando…
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
BACKGROUND: The purpose of this paper is to present the results of statistical analysis of spot baseline urinary norepinephrine and epinephrine assays in correlation with spot baseline urinary serotonin and dopamine findings previously published by the authors. Our research indicates a need for phys...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818932/ https://www.ncbi.nlm.nih.gov/pubmed/24198631 http://dx.doi.org/10.2147/OAJU.S16637 |
_version_ | 1782289926873677824 |
---|---|
author | Hinz, Marty Stein, Alvin Uncini, Thomas |
author_facet | Hinz, Marty Stein, Alvin Uncini, Thomas |
author_sort | Hinz, Marty |
collection | PubMed |
description | BACKGROUND: The purpose of this paper is to present the results of statistical analysis of spot baseline urinary norepinephrine and epinephrine assays in correlation with spot baseline urinary serotonin and dopamine findings previously published by the authors. Our research indicates a need for physicians and decision-makers to understand the lack of validity of this type of spot baseline monoamine testing when using it in the decision-making process for neurotransmitter deficiency disorders. METHODS: Matched-pairs t-tests were performed for a group of subjects for whom spot baseline urinary norepinephrine and epinephrine assays were performed on samples collected on different days then paired by subject. RESULTS: The reported laboratory test results for urinary serotonin, dopamine, norepinephrine, and epinephrine, obtained on different days from the same subjects, differed significantly and were not reproducible. CONCLUSION: Spot baseline monoamine assays, in subjects not suffering from a monoamine-secreting tumor, such as pheochromocytoma or carcinoid syndrome, are of no value in decision-making due to this day-to-day variability and lack of reproducibility. While there have been attempts to integrate spot baseline urinary monoamine assays into treatment of peripheral or central neurotransmitter-associated disease states, diagnosis of neurotransmitter imbalances, and biomarker applications, significant differences in day-to-day reproducibility make this impossible given the known science as it exists today. |
format | Online Article Text |
id | pubmed-3818932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38189322013-11-06 Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine Hinz, Marty Stein, Alvin Uncini, Thomas Open Access J Urol Original Research BACKGROUND: The purpose of this paper is to present the results of statistical analysis of spot baseline urinary norepinephrine and epinephrine assays in correlation with spot baseline urinary serotonin and dopamine findings previously published by the authors. Our research indicates a need for physicians and decision-makers to understand the lack of validity of this type of spot baseline monoamine testing when using it in the decision-making process for neurotransmitter deficiency disorders. METHODS: Matched-pairs t-tests were performed for a group of subjects for whom spot baseline urinary norepinephrine and epinephrine assays were performed on samples collected on different days then paired by subject. RESULTS: The reported laboratory test results for urinary serotonin, dopamine, norepinephrine, and epinephrine, obtained on different days from the same subjects, differed significantly and were not reproducible. CONCLUSION: Spot baseline monoamine assays, in subjects not suffering from a monoamine-secreting tumor, such as pheochromocytoma or carcinoid syndrome, are of no value in decision-making due to this day-to-day variability and lack of reproducibility. While there have been attempts to integrate spot baseline urinary monoamine assays into treatment of peripheral or central neurotransmitter-associated disease states, diagnosis of neurotransmitter imbalances, and biomarker applications, significant differences in day-to-day reproducibility make this impossible given the known science as it exists today. Dove Medical Press 2011-02-04 /pmc/articles/PMC3818932/ /pubmed/24198631 http://dx.doi.org/10.2147/OAJU.S16637 Text en © 2011 Hinz et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Hinz, Marty Stein, Alvin Uncini, Thomas Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
title | Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
title_full | Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
title_fullStr | Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
title_full_unstemmed | Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
title_short | Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
title_sort | urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818932/ https://www.ncbi.nlm.nih.gov/pubmed/24198631 http://dx.doi.org/10.2147/OAJU.S16637 |
work_keys_str_mv | AT hinzmarty urinaryneurotransmittertestingconsiderationsofspotbaselinenorepinephrineandepinephrine AT steinalvin urinaryneurotransmittertestingconsiderationsofspotbaselinenorepinephrineandepinephrine AT uncinithomas urinaryneurotransmittertestingconsiderationsofspotbaselinenorepinephrineandepinephrine |